Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The European Medicines Agency has announced the establishment of the Data Analysis and Real World Interrogation Network (DARWIN EU®) to support better decision making on the development and effectiveness of medicines and vaccines.

DARWIN EU®, will deliver real-world evidence from across Europe on the use, safety, and effectiveness of medicines for human use, including vaccines, from real-world healthcare databases across the European Union (EU).

Erasmus University Medical Centre has been named as the Coordination Centre for DARWIN EU®. Its role is to develop and manage a network of real-world healthcare data sources across the EU and to conduct scientific studies requested by medicines regulators and, at a later stage, requested by other stakeholders.

NDORMS has been subcontracted to the Coordination Centre to contribute analytics and data to the analysis of drug and vaccine safety.

Daniel Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology described the initiative as a gamechanger in the way drug studies will be performed internationally to benefit patients and healthcare professionals. He said: "Our Pharmaco- and Device Epidemiology team at NDORMS will be one of the key contributors to this initiative. With our knowledge of statistics, epidemiology, and health data sciences, we will co-lead on the design and programming of analytical pipelines for the study of the use, safety, and effectiveness of medicines and vaccines in Europe."

DARWIN EU® will be able to leverage the existing work Oxford has contributed to within the European Health Data and Evidence Network (EHDEN) project funded by the Innovative Medicines Initiative (IMI), and the Observational Health Data Sciences and Informatics (OHDSI) community.

"DARWIN EU® will be transformative for the use of real-world healthcare data in Europe. Building on our work from before and during the COVID-19 pandemic on conducting research using databases from across Europe, we will be establishing the analytic pipelines to rapidly generate evidence to inform regulatory decision making while maintaining patient privacy and ensuring methodological rigour," said Ed Burn, Senior Researcher in Epidemiology and Health Economics at NDORMS.

The vision of DARWIN EU® is to give EMA and national competent authorities in EU Member States access to valid and trustworthy real-world evidence, for example on diseases, patient populations, and the use, safety and effectiveness of medicines, including vaccines, throughout the lifecycle of a medicinal product.

By supporting decision-making on the development, authorisation and surveillance of medicines, a wide range of stakeholders will benefit, from patients and healthcare professionals to health technology assessment bodies and the pharmaceutical industry. Additionally, DARWIN EU® will provide an invaluable resource to prepare for and respond to future healthcare crises and pandemics.

More from Professor Daniel Prieto-Alhambra and Ed Burn.

Similar stories

Emergency to use the FORCE pathway for wrist fractures in children

New research from the University of Oxford has shown that doctors can simplify treatment for the most common fracture in children, reducing NHS costs.

Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.